67 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Novel inhibitors of alpha 4 beta 1 integrin receptor interactions through library synthesis and screening.
University of California
22
Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.
Ranbaxy Research Laboratories
20
Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
Hoffmann-La Roche
16
Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.
Hoffmann-La Roche
19
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
Daiichi Sankyo
20
Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
Daiichi Sankyo
9
LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line.
University of Louvain
2
Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.
University of California
14
Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Merck Research Laboratories
31
Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
Daiichi Sankyo
9
Influence of acid surrogates toward potency of VLA-4 antagonist.
Merck Research Laboratories
20
Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
Daiichi Pharmaceutical
13
Identification of potent and novel alpha4beta1 antagonists using in silico screening.
Biogen
74
Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.
Genentech
14
N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.
Merck Research Laboratories
20
N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.
Merck Research Laboratories
5
Identification of unique VLA-4 antagonists from a combinatorial library.
Merck Research Laboratories
26
N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
Celltech R&D
19
Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
Celltech R&D
21
N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
Merck Research Laboratories
12
Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent alpha(4)beta(1) integrin antagonists.
Pfizer
13
Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists.
Hoffmann-La Roche
13
Discovery and evaluation of potent, cysteine-based alpha4beta1 integrin antagonists.
Celltech Chiroscience
36
N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Hoffmann-La Roche
28
Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Elan Pharmaceuticals
14
Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.
Millennium Pharmaceuticals
30
Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.
Johnson & Johnson Pharmaceutical Research & Development
37
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.
Genentech
8
Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
Merck Research Laboratories
39
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.
Nerviano
21
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Johnson & Johnson Pharmaceutical Research & Development
38
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
65
N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.
Merck Research Laboratories
17
Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.
Genentech
47
N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Roche Research Center
6
Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists.
Roche Research Center
14
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.
University of California San Francisco
39
Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
Merck Research Laboratories
46
Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
Merck Research Laboratories
30
The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
Merck Research Laboratories
19
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
University of Bologna
25
The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Merck Research Laboratories
12
Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.
Merck Research Laboratories
8
Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.
Bayer
22
Design and synthesis of potent and selective inhibitors of integrin VLA-4.
Novartis Institute For Biomedical Research
53
The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.
Merck Research Laboratories
16
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
Pliant Therapeutics
15
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.
Celltech Chiroscience
6
N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.
Roche Research Center
5
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Dupont Pharmaceuticals
13
Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
Biogen
14
Could Dissecting the Molecular Framework of β-Lactam Integrin Ligands Enhance Selectivity?
University of Bologna
13
Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.
Dupont Pharmaceuticals
7
Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.
University of Bologna
